ICPerMed conference


Paula Pohlmann

The University of Texas MD Anderson Cancer Center, USA


Precision medicine in the treatment of patients with breast cancer: the I-SPY trials’ experience Dr Pohlmann is a board-certified medical oncologist specializing in phase I clinical trials and in breast cancer research and treatment. After completing medical studies and postgraduation at the Federal University of Rio Grande do Sul in Brazil, Dr. Pohlmann received the Kalf Fellowship/Career Development Award for studies on breast cancer immunology at the Vrije Universiteit in Amsterdam. She subsequently worked at the Vanderbilt University in Nashville, TN on therapeutic MAbs pharmacology, serum proteomics and biomarker development, leading to 4 patents later licensed for development by industry. She completed clinical retraining in both Medicine and Hematology-Oncology at the Vanderbilt University Medical Center, subsequently joining Vanderbilt Faculty. She became an I-SPY 2 clinical investigator in 2013, when she joined the Breast Cancer Program of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC. In 2021, Dr Pohlmann joined the Department of Breast Medical Oncology of the University of Texas MD Anderson Cancer Center. She has a secondary appointment at the Department of Investigational Cancer Therapeutics. At the MDACC, Dr Pohlmann serves at the Advisory Council of Clinical Research Leaders and as the Chief of Clinical Research of the Breast Medical Oncology Department. Dr Pohlmann currently serves as an I-SPY 2.2 investigator, as member of the I-SPY Safety and New Agents Committees and as the PRE-ISPY/I-SPY Phase IB national leader.